1 |
Molecular Docking studies of FKBP12-mTOR inhibitors using binding predictions |
미소장 |
2 |
A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin |
미소장 |
3 |
mTOR complex 2 signaling and functions |
미소장 |
4 |
Nano‐Self‐Assembly of Nucleic Acids Capable of Transfection without a Gene Carrier |
미소장 |
5 |
mTOR Signaling in Growth Control and Disease |
미소장 |
6 |
Characterization of the FKBP·Rapamycin·FRB Ternary Complex |
미소장 |
7 |
FK-506, a potent novel immunosuppressive agent, binds to a cytosolic protein which is distinct from the cyclosporin A-binding protein, cyclophilin. |
미소장 |
8 |
New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation |
미소장 |
9 |
mTOR inhibitors in cancer therapy |
미소장 |
10 |
mTOR Signaling in Growth, Metabolism, and Disease |
미소장 |
11 |
mTORC1 signaling and the metabolic control of cell growth |
미소장 |
12 |
Mammalian target of rapamycin (mTOR) as a potential therapeutic target in various diseases |
미소장 |
13 |
mTOR Pathways in Cancer and Autophagy |
미소장 |
14 |
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy |
미소장 |
15 |
Metabolic regulation of cell growth and proliferation |
미소장 |
16 |
mTOR in Human Diseases |
미소장 |
17 |
Targeting mTOR for cancer therapy |
미소장 |
18 |
PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges |
미소장 |
19 |
Mechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeutics |
미소장 |
20 |
Dual-Targeted Delivery of Nanoparticles Encapsulating Paclitaxel and Everolimus: a Novel Strategy to Overcome Breast Cancer Receptor Heterogeneity |
미소장 |
21 |
mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges |
미소장 |
22 |
<p>Nanotechnology-Based Targeting of mTOR Signaling in Cancer</p> |
미소장 |
23 |
Research progress of mTOR inhibitors |
미소장 |
24 |
Dendrimer-Mediated Targeted Delivery of Rapamycin to Tumor-Associated Macrophages Improves Systemic Treatment of Glioblastoma |
미소장 |
25 |
Targeted delivery of heat shock protein 90 inhibitors prevents growth of HER2-positive tumor |
미소장 |
26 |
The Potential of Topoisomerase Inhibitor-Based Antibody–Drug Conjugates |
미소장 |
27 |
Overview of Research into mTOR Inhibitors |
미소장 |
28 |
Recent advances and limitations of mTOR inhibitors in the treatment of cancer |
미소장 |
29 |
Small molecule inhibitors targeting the cancers |
미소장 |
30 |
Drug conjugate-based anticancer therapy - Current status and perspectives |
미소장 |